Anti-PD-L1 therapy prolonged the tumor-doubling time to 18.3 days vs. 9.8 in the appropriate control (p = 0.001), whereas we did not find a significant increase in the index value in the low-grade treatment group. This evidence concerns the gene CD274 and neoplasm.